Literature DB >> 32549952

Stabilization of Progressive Multifocal Leukoencephalopathy After Pembrolizumab Treatment.

Ronak K Kapadia1,2, Douglas Ney2.   

Abstract

Entities:  

Keywords:  central nervous system infections; central nervous system viral diseases; demyelinating diseases; leukoencephalopathy; pembrolizumab; progressive multifocal

Year:  2020        PMID： 32549952      PMCID： PMC7271622          DOI： 10.1177/1941874420902872

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN： 1941-8744


× No keyword cloud information.
  1 in total

1.  Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.

Authors:  Irene Cortese; Pawel Muranski; Yoshimi Enose-Akahata; Seung-Kwon Ha; Bryan Smith; MariaChiara Monaco; Caroline Ryschkewitsch; Eugene O Major; Joan Ohayon; Matthew K Schindler; Erin Beck; Lauren B Reoma; Steve Jacobson; Daniel S Reich; Avindra Nath
Journal:  N Engl J Med       Date:  2019-04-10       Impact factor: 91.245
  1 in total
  4 in total

Review 1.  Promise and Challenges of Checkpoint Inhibitor Therapy for Progressive Multifocal Leukoencephalopathy in HIV.

Authors:  Sydney Corey; Bryan R Smith; Irene C M Cortese
Journal:  Curr HIV/AIDS Rep       Date:  2022-10-01       Impact factor: 5.495

2.  Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review.

Authors:  Tulika Chatterjee; Moni Roy; Rone-Chun Lin; Mohammad O Almoujahed; Sharjeel Ahmad
Journal:  IDCases       Date:  2022-05-20

Review 3.  Innovative therapeutic concepts of progressive multifocal leukoencephalopathy.

Authors:  Nora Möhn; Lea Grote-Levi; Franziska Hopfner; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Clemens Warnke; Kurt-Wolfram Sühs; Mike P Wattjes; Günter U Höglinger; Thomas Skripuletz
Journal:  J Neurol       Date:  2022-01-07       Impact factor: 6.682

4.  Sequential treatment of progressive multifocal leukoencephalopathy with intravenous immunoglobulins and pembrolizumab.

Authors:  Fabian Boesl; Kristina Allers; Juliane Herm; Thomas Scheider; Christiana Franke
Journal:  J Neurovirol       Date:  2022-03-23       Impact factor: 3.739
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.